1. Home
  2. CTNM vs FLGT Comparison

CTNM vs FLGT Comparison

Compare CTNM & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

SELL

Current Price

$9.57

Market Cap

550.7M

Sector

N/A

ML Signal

SELL

Logo Fulgent Genetics Inc.

FLGT

Fulgent Genetics Inc.

SELL

Current Price

$24.18

Market Cap

511.0M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CTNM
FLGT
Founded
2009
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
550.7M
511.0M
IPO Year
2024
2016

Fundamental Metrics

Financial Performance
Metric
CTNM
FLGT
Price
$9.57
$24.18
Analyst Decision
Buy
Analyst Count
8
0
Target Price
★ $21.43
N/A
AVG Volume (30 Days)
★ 596.9K
324.7K
Earning Date
11-03-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 0.46
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $18,730,000.00
Revenue This Year
N/A
$3.85
Revenue Next Year
N/A
$9.64
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$6.73
$13.46
52 Week High
$17.79
$31.04

Technical Indicators

Market Signals
Indicator
CTNM
FLGT
Relative Strength Index (RSI) 46.25 59.62
Support Level $8.59 $18.82
Resistance Level $13.72 $24.91
Average True Range (ATR) 0.77 1.42
MACD 0.23 0.43
Stochastic Oscillator 42.33 64.10

Price Performance

Historical Comparison
CTNM
FLGT

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

About FLGT Fulgent Genetics Inc.

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.

Share on Social Networks: